Get the Stockscreener App
12.82
3.61%
-0.48
After Hours:
12.82
Lyell Immunopharma Inc stock is traded at $12.82, with a volume of 32,402.
It is down -3.61% in the last 24 hours and up +21.29% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$13.30
Open:
$13.41
24h Volume:
32,402
Relative Volume:
0.39
Market Cap:
$246.29M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-16.23
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+5.51%
1M Performance:
+21.29%
6M Performance:
-4.54%
1Y Performance:
-44.26%
1-Day Range:
$12.68
$13.41
1-Week Range:
$12.15
$13.50
52-Week Range:
$7.65
$32.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
12.82 | 251.09M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Multi asset correlation models including Lyell Immunopharma Inc.Weekly Trading Summary & Community Verified Trade Signals - Newser
Sector ETF performance correlation with Lyell Immunopharma Inc.Earnings Overview Report & Weekly Watchlist of Top Performers - Newser
Detecting support and resistance levels for Lyell Immunopharma Inc.2025 Pullback Review & Pattern Based Trade Signal System - Newser
Best data tools to analyze Lyell Immunopharma Inc. stockJuly 2025 Trends & Growth Oriented Trade Recommendations - Newser
Does Lyell Immunopharma Inc. fit your quant trading modelChart Signals & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about Lyell Immunopharma Inc.Quarterly Profit Review & AI Based Buy and Sell Signals - Newser
Price action breakdown for Lyell Immunopharma Inc.2025 Major Catalysts & Long Hold Capital Preservation Plans - Newser
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decrease in Short Interest - MarketBeat
What machine learning models say about Lyell Immunopharma Inc.July 2025 Earnings & Technical Buy Zone Confirmations - Newser
Ranking Lyell Immunopharma Inc. among high performing stocks via toolsJuly 2025 Reactions & Community Supported Trade Ideas - Newser
Invesco Ltd. Has $204,000 Stake in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Will Lyell Immunopharma Inc. stock go up soonWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
What technical models suggest about Lyell Immunopharma Inc.’s comebackQuarterly Portfolio Report & Reliable Breakout Forecasts - Newser
How to build a dashboard for Lyell Immunopharma Inc. stockGDP Growth & Safe Capital Growth Tips - Newser
ranking lyell immunopharma inc. among high performing stocks via toolsPortfolio Update Summary & Entry Point Strategy Guides - Newser
Nuveen LLC Invests $345,000 in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Multi factor analysis applied to Lyell Immunopharma Inc.2025 Fundamental Recap & Accurate Trade Setup Notifications - Newser
Is Lyell Immunopharma Inc. stock poised for growthJuly 2025 Patterns & Capital Efficiency Focused Ideas - Newser
Published on: 2025-09-10 00:57:57 - Newser
Order flow analysis tools used on Lyell Immunopharma Inc.Trade Risk Assessment & Long-Term Safe Investment Ideas - Newser
Real time scanner hits for Lyell Immunopharma Inc. explainedJuly 2025 Opening Moves & Stock Market Timing Techniques - Newser
Using RSI to spot recovery in Lyell Immunopharma Inc.2025 Earnings Impact & Short-Term High Return Ideas - Newser
Visual trend scoring systems applied to Lyell Immunopharma Inc.Market Volume Report & Accurate Intraday Trade Tips - Newser
What momentum shifts mean for Lyell Immunopharma Inc.2025 Historical Comparison & AI Based Buy and Sell Signals - Newser
Is Lyell Immunopharma Inc. stock trending bullishEarnings Growth Summary & High Return Trade Guides - beatles.ru
Should value investors consider Lyell Immunopharma Inc.2025 Winners & Losers & Safe Capital Growth Tips - 뉴스영
Using Bollinger Bands to evaluate Lyell Immunopharma Inc.Market Sentiment Review & Verified Technical Trade Signals - Newser
Almitas Capital LLC Acquires 1,432,086 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
Published on: 2025-09-08 09:31:15 - beatles.ru
Can Lyell Immunopharma Inc. reach all time highs this year - beatles.ru
Using data models to predict Lyell Immunopharma Inc. stock movementJuly 2025 Fed Impact & Daily Market Momentum Tracking - Newser
Charles Schwab Investment Management Inc. Sells 41,111 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):